WO2007001839A2 - 4-anilino-3-quinolinecarbonitriles for the treatment of cancer - Google Patents
4-anilino-3-quinolinecarbonitriles for the treatment of cancer Download PDFInfo
- Publication number
- WO2007001839A2 WO2007001839A2 PCT/US2006/023063 US2006023063W WO2007001839A2 WO 2007001839 A2 WO2007001839 A2 WO 2007001839A2 US 2006023063 W US2006023063 W US 2006023063W WO 2007001839 A2 WO2007001839 A2 WO 2007001839A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- assay
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 201000011510 cancer Diseases 0.000 title claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 12
- 229960005277 gemcitabine Drugs 0.000 claims description 12
- 229940120638 avastin Drugs 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 description 26
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000007995 HEPES buffer Substances 0.000 description 15
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000000021 kinase assay Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- WZPHVAQRLIJTLG-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-5-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=C(OC)C=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl WZPHVAQRLIJTLG-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000006180 TBST buffer Substances 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- -1 Yes Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229910052693 Europium Inorganic materials 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 4
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 4
- 229960003736 bosutinib Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- 108060006706 SRC Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091007381 CBL proteins Proteins 0.000 description 2
- 102000009193 Caveolin Human genes 0.000 description 2
- 108050000084 Caveolin Proteins 0.000 description 2
- 101100503637 Danio rerio fynb gene Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101150099493 STAT3 gene Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QUDAEJXIMBXKMG-UHFFFAOYSA-N 1-[2-[[2-[2-[[6-amino-2-[[2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CO)C(=O)NCC(=O)N1CCCC1C(O)=O QUDAEJXIMBXKMG-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GASHKCRNJZBFBE-UHFFFAOYSA-N 7-(3-chloropropoxy)-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCCl)C=C3N=CC=2C#N)=C1Cl GASHKCRNJZBFBE-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102100025227 Calcium/calmodulin-dependent protein kinase type II subunit gamma Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 102000010958 Cortactin Human genes 0.000 description 1
- 108010037663 Cortactin Proteins 0.000 description 1
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000057592 human Raf1 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000024011 parotid gland neoplasm Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention is directed to a method of using 4-(2,4-dichloro-5- methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-l-yl)-propoxy]- quinoline-3-carbonitrile (SKI-606), the compound of formula (I), to treat cancer and a composition containing the same.
- Patents Nos. 6,002,008, 6,384,051, 6,432,979 and 6,617,333 disclose certain A- anilino-3-quinolmecarbomtriles derivatives that are shown to possess anti-tumor activity.
- the protein tyrosine kinases consist of functionally related receptor and nonreceptor signaling enzymes regulating cell growth, activation, differentiation, development, and transformation through phosphorylation of specific tyrosine residues.
- the receptor tyrosine kinases such as epidermal growth factor receptor
- EGFR extracellular ligand binding domain
- a single transmembrane domain an intracellular tyrosine kinase domain.
- the nonreceptor tyrosine kinases such as Src and AbI, are soluble cytoplasmic enzymes with multiple regulatory and protein-binding domains.
- the Src tyrosine kinase family is a group of 9 nonreceptor tyrosine kinases defined by both functional and sequence similarity. Three members of this family are widely expressed: Src, Yes, and FynB. The other 6 members,
- Lck, Lyn, FynT, Fgr, Hck, and BIk are predominantly expressed in hematopoietic cells.
- Extensive reviews on structure and function of nonreceptor protein tyrosine kinases and their relevance in human cancers have been published.
- the Src nonreceptor protein tyrosine kinase is the prototype of the Src family. Src is a key downstream component of pathways mediated by growth factor receptors and G-protein coupled receptors, and is believed to coordinate signals from these various pathways.
- the list of intracellular target proteins known to be phosphorylated by Src-family kinases is large and continues to grow, including integrins, adhesion kinases, cadherins, stat3, cortactin, ezrin, focal adhesion proteins (FAK), and many others.
- Src is upregulated in most cancers including the vast majority of pancreatic, melanoma, head and neck, and ovarian cancers. Src is also activated in prostatic tumor lines. Src mRNA levels were higher in human parotid tumors compared to normal tissue samples. Barrett's esophagus and esophageal carcinomas also overexpress Src.
- the present invention is directed to a method of preventing, treating or inhibiting cancer comprising, administering a therapeutically effective amount of a compound of formula (I):
- This invention is also directed to a method of treating pancreatic cancer comprising, administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, in combination with gemcitabine, or a pharmaceutically acceptable salt thereof.
- Another aspect of this invention is a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Figure 1 Shows the response of the head and neck line HN5 to 4-[(2,4- dichloro-5-methoxyphenyl) amino]-5-methoxy-7-[3-(4-methyl- 1 -piperazinyl) propoxy]-3-quinoline carbonitrile.
- DETAILED DESCRIPTION OF THE INVENTION [0013]
- the term "cancer” refers to any malignant growth or tumor caused by abnormal and uncontrolled cell division. It may spread to other parts of the body through the lymphatic system or the blood stream. For the purposes of the method of treating cancer described in this application, cancer includes pancreatic, lymphatic and prostate cancers.
- salts are those derived from such organic and inorganic acids as: acetic, lactic, carboxylic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known acceptable acids.
- the compound of formula (I) may be provided orally, by intralesional, intraperitoneal, intramuscular or intravenous injection, infusion, liposome- mediated delivery, topical, nasal, anal, vaginal, sublingual, uretheral, transdermal, intrathecal, ocular or otic delivery.
- the compound is in the form of the unit dose.
- Suitable unit dose forms include tablets, capsules and powders in sachets or vials.
- Such unit dose forms may contain from 0.1 to 300 mg of the compound of formula (I), and preferably from 2 to 100 mg.
- Still further preferred unit dosage forms contain 50 to 150 mg of the compound of formula (I).
- the compound of formula (I) can be administered orally. It may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.
- the effective amount will be known to one of skill in the art; it will also be dependent upon the form of the compound.
- One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer.
- This invention is also directed to pharmaceutical compositions containing a therapeutically effective amount of 4-(2,4-dichloro-5-methoxy- phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-l-yl)-propoxy]-quinoline-3- carbonitrile, the compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
- the carrier may be, for example, a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier.
- the carrier may be a polymer or a toothpaste.
- a carrier in this invention encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules.
- the compositions containing the compound of formula (I) may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent or a color additive.
- such compounds When provided orally or topically, such compounds would be provided to a subject by delivery in different carriers.
- such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, or glycols.
- the specific carrier would need to be selected based upon the desired method of delivery, for example, phosphate buffered saline (PBS) could be used for intravenous or systemic delivery and vegetable fats, creams, salves, ointments or gels may be used for topical delivery.
- PBS phosphate buffered saline
- the compound of formula (I) may be delivered together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in treatment or prevention of neoplasm.
- suitable diluents for example, Tris-HCl, acetate, phosphate), pH and ionic strength, additives such as albumins or gelatin to prevent absorption to surfaces, detergents (for example, TWEEN 20, TWEEN 80, PLURONIC F68, bile acid salts), solubilizing agents (for example, glycerol, polyethylene glycerol), anti-oxidants (for example ascorbic acid, sodium metabisulfate), preservatives (for example, thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (for example, lactose, mannitol), covalent attachment
- buffer content for example, Tris-HCl, acetate, phosphate
- compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the compound or composition.
- the choice of compositions will depend on the physical and chemical properties of the compound capable of treating or preventing a neoplasm.
- the compound of formula (I) may be delivered locally via a capsule that allows a sustained release of the compound over a period of time.
- Controlled or sustained release compositions include formulation in lipophilic depots (for example, fatty acids, waxes, oils).
- the present invention further provides a method of using the compound of formula (I) as an active therapeutic substance for preventing treating and/or inhibiting cancer.
- SKI-606 is useful in preventing, treating or inhibiting cancers by suppressing proliferation of malignant cells.
- SKI-606 inhibits Src catalyzed phosphorylation of intercellular proteins associated with cell proliferation. Therefore, dosing a human with a therapeutically effective amount of SKI-606 can prevent or inhibit the formations of cancers by suppressing proliferation, or can treat a human already suffering from a cancer by preventing or inhibiting further growth of tumors and/or causing a reduction in size or the eradication of tumors.
- the term “inhibition” refers to retardation, suppression or stopping of malignant cell proliferation, presumably by blocking, or suppressing phophorylation catalyzed by Src.
- the term “preventing” refers to averting or forestalling the development of malignant or tumoric growths by prophylatic treatment, or to impede, inhibit or cease further progression of the disease.
- treating refers to administering to a patient in need thereof a therapeutically effective amount of SKI-606 in order to prophylactically prevent the development of a cancer, to inhibit or cease the progression of a cancer, or a malignant or tumoric growth, to reverse the progression of a cancer, or a malignant or tumoric growth, or to eradicate a cancer, or a malignant or tumoric growth.
- the present invention further provides a method of treating cancer in humans, which comprises administering to the infected individual an effective amount of 4-(2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl- piperazin-l-yl)-propoxy]-quinoline-3-carbonitrile, a pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing the same.
- the dose provided to a patient will vary depending upon what is being administered, the purpose of the administration, the manner of administration, and the like.
- terapéuticaally effective amount is an amount sufficient to cure or ameliorate symptoms of a cancer.
- the compound of formula (I) may be delivered alone or in combination with other compounds used to treat cancer.
- Such compounds include but are not limited to imatinib mesylate (GLEEVEC), hydroxyurea, IFN- ⁇ , cytotoxic agents, chemotherapeutic agents, NSAIDS, gemcitabine, EGFR inhibitors, MEK inhibitors, farnesyltransferase, gemcitabine, avastin or wortmannin, or pharmaceutically acceptable salts thereof.
- a preferred embodiment of the method of the present invention comprises administering a therapeutically effective amount of the compound of formula (I) in combination with a therapeutically effective amount of gemcitabine or avastin. More preferably the compound of formula (I) is administered in combination with gemcitabine.
- Another preferred embodiment of the method of the present invention comprises administering a therapeutically effective amount of the compound of formula (I) in combination with a therapeutically effective amount of gemcitabine and avastin.
- Another preferred embodiment of the method of the present invention involves administering the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with gemcitabine and avastin, or pharmaceutically acceptable salts thereof, to treat pancreatic cancer.
- a preferable compound for practicing the method and/or for use in a composition of this invention is 4-(2,4-dichloro-5-methoxy-phenylamino)-6- methoxy-7-[3-(4-methyl-piperazin-l-yl)-propoxy]-quinoline-3-carbonitrile and a pharmaceutically acceptable salt thereof.
- the compound of Formula (I) is readily obtained by treatment of 7-(3- chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3- quinolinecarbonitrile with N-methylpiperazine in the presence of sodium iodide either neat or in a solvent such as ethylene glycol dimethyl ether.
- N-methylpiperazine a solvent such as ethylene glycol dimethyl ether
- Figure 1 Response of the head and neck tumor line HN5 to 4-[(2,4- dichloro-5-methoxyphenyl)amino]-5-methoxy-7-[3-(4-methyl-l- piperazinyl)propoxy]-3-quinolinecarbonitrile.
- Serum-starved HN5 cells were treated with the compound for 4 hours, after which EGF was added to 50 ng/ml for ten minutes. Lysates were analyzed for Stat3 Y705, c-Cbl Y731 and Y774 and caveolin Y14 phosphorylation.
- the compound of formula (I) inhibits Src catalyzed phosphorylation of a target peptide.
- 4-[(2,4-dichloro-5-methoxyphenyl)ammo]-5-methoxy-7-[3-(4- methyl-l-piperazinyl)propoxy3-3-quinolinecarbonitrile inhibited Src catalyzed phosphorylation in a homogeneous enzyme assay (FRET/Lance format) with an IC50 of 3.5 nM.
- Compound was added with a final DMSO concentration of 1 %, and incubated for ten minutes at 37°C for Src assay and 27 0 C for AbI assay.
- the kinase reaction was initiated by addition of ATP to a final concentration of 100 ⁇ M, and incubated for 70 minutes at 37°C for Src, and 30 minutes at 27°C for AbI.
- the reaction was stopped with EDTA at a final concentration of 3OmM EDTA/25mM Hepes (pH 7.5)/10 ⁇ g/ml BSA.
- the mixture was combined with Eu-labeled phosphotyrosine antibody PT66 (Perkin Elmer, AD0068) and Streptavidin Surelight-APC (Perkin Elmer, CR130-100) in 50 mM Hepes (pH 7.5)/ 20 ⁇ g/ml BSA, and incubated for 30 min according to manufacturer's specifications. The reaction was monitored on a Wallac Victor with excitation at 340 ran and emission at 665 nm. Data was analyzed with the LSW data analysis plug-in for Excel (Microsoft).
- PKA, PKC, S6 kinase, CAMKII and p38 kinase assays are used for the kinase assay with PKA (Upstate #14- 114), PKC (Upstate #14-232) and S6K (Upstate #14-333).
- An ELISA format is used for CAMK-II (Upstate # 14-217 and p38 (Recombinant protein produced and purified in house) SCINTIPLATE ASSAY
- the volumes showed in the following table are for one 96 well plate.
- p38 is activated with a dominant active mutant of MKK6.
- Peptide 1738 MK2 T334: Bio-QSTKVPQTPLHTSRVL
- Peptide 1895 Gastrin 1-17: Bio-KKEGPWLEEEEEAYGWMD
- the kinase assay is performed in the same fashion as the scintiplate assay: See step 1 through 3 above.
- the detection plate is a TMunc MaxiSorb precoated with Amersham goat anti-GST antibody 1 :400 in PBS at 100 ul/well for 2 hours.
- the reaction plate is a Costar polysterene plate preblocked with blocking buffer at 0.1% Gelatin for two hours with 200 ul/well.
- Antibodies For the detection of phosphorylated peptide, affinity purified polyclonal phospho-specific antibodies 60521 and 64273 are used against 1323 and 1738 respectively.
- Reagents Sf9 insect cell lysate containing full length 6his-tagged recombinant human c-Raf. (Specific Activity: ⁇ 200U/ml). Human Non-active Mek-1-GST and human GST-MAP kinase (recombinant proteins produced in E.coli ). Rafl Kinase Cascade Assay Procedure:
- Raf-1 (c-Raf) is used to phosphorylate and activate inactive GST-MEKl which then can phosphorylate and activate inactive p42 GST-MAPK, which subsequently is measured for phosphorylation of the TEY sequence (aa's 202-204) by a phospho-specific antibody from Sigma (cat. # 77439219041)
- Assay Dilution Buffer 2OmM MOPS, pH 7.2, 25mM ⁇ -glycerol phosphate, 5mM EGTA, ImM sodium orthovanadate, ImM dithiothreitol.
- Magnesium/ATP Cocktail 500 ⁇ M cold ATP and 75 mM magnesium chloride in ADB.
- Active Kinase Human Active c-Raf: Use at 0.4U per assay point.
- Non-active GST-MEKl Use at 0.1 ⁇ g per assay point.
- Non-active GST-p42 MAP Kinase Use at 1.0 ⁇ g per assay point.
- Peptide substrate poly(Glu4-Tyr), Sigma (P-0275): Prepare 5 mg/ml stock in water.
- TBS BupH TBS Pierce (#28376); 25 mM Tris pH 7.2, 150 mM NaCl final
- Enzyme diluent 0.1% BSA in 4 mM HEPES, pH 7.4
- ATP (FW 551): AmershamPharmacia #27-2056-01 (25 umol): 100 mM stock 11); 250 mM MgC12: Sigma M-8266, anhydrous, FW 95.21; 1.19 g/ 50 ml water
- Eu-anti-PY (PT66): PerkinElmer AD0040 (50 ug, Sigma clone PT66, anti- phosphotyrosine antibody).
- Raw europium (fluorescence) counts are converted to percent inhibition and/or IC50 based on untreated (no compound) control wells using Excel templates.
- IC 5O Concentration at which there is 50% inhibition.
- the compounds of formula (I) is a selective inhibitor of Src kinase family kinases and AbI kinases.
- Cell-based assays were also used to examine the selectivity of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-5-methoxy-7-[3-(4- methyl-l-piperazinyl)propoxy]-3-quinolinecarbonitrile.
- Rat fibroblasts overexpressing an oncogenic form of Src, where the catalytic domain of human c-Src was inserted in place of the v-Src catalytic domain to create a fusion v- Src/human c-Src protein.
- Table 2 shows proliferation data obtained for 4-[(2,4-dichloro-5- methoxyphenyl)ammo]-5-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3- quinolinecarbonitrile under these conditions.
- IC50 Concentration at which there is 50% inhibition.
- Compounds of formula (I) are potent inhibitors of tumor cell proliferation in head and neck cell lines that overexpress Src.
- a representative proliferation profile of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-5-methoxy-7-[3-(4-methyl- l-piperazinyl)propoxy]-3-quinolinecarbonitrile with the HN5 line is shown in Figure 1, along with evidence for inhibition of phosphorylation of downstream target proteins.
- the CellTiter-Glo luminescent cell viability assay (Promega # G7573) was used where cells were lysed with the CellTiter GIo reagent, agitated briefly and allowed to sit at room temperature for 30 minutes prior to analyzing on a Wallac plate reader equipped for luminescence readings.
- the sulforhodamine B (SRB) assay was used for certain melanoma lines.
- the serum concentration in the growth medium was 5% and culture medium volume was 0.2 ml.
- 0.05 ml of 50% trichloroacetic acid was added to the medium and the plate was allowed to sit at room temperature for 1 hour. The medium was decanted and the plate was washed 3 times with water. The washed plates were dried, and then 0.08 ml of SRB reagent (SRB was obtained from Sigma; 0.4% SRB in 1% acetic acid) was added. After 10 minutes at room temperature, the plates were washed with 1% acetic acid until no free red color remained in solution. The bound SRB reagent was solubilized with 0.15 ml 10 mM Tris (no acid added). After agitating for 5 minutes on a shaker, the absorbance was read at 540 nM.
- Table 3 summarizes the proliferation assay results obtained upon treating T-cell leukemia, prostate, pancreatic, melanoma and head and neck tumor lines with 4-(2,4-dichloro-5-methoxy- ⁇ henylamino)-6-methoxy-7-[3-(4-methyl- piperazin-l-yl)-propoxy]-quinoline-3-carbonitrile. Also shown is the ability of 4- (2,4-dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-l- yl)-propoxy]-quinoline-3-carbonitrile administration to retard the growth of A375 melanoma subcutaneous tumor xenografts in nude mice.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008518219A JP2008546777A (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitrile for the treatment of cancer |
MX2007016542A MX2007016542A (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer. |
CA002610209A CA2610209A1 (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer |
EP06773093A EP1893209A2 (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer |
AU2006262591A AU2006262591A1 (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer |
BRPI0611977-8A BRPI0611977A2 (en) | 2005-06-24 | 2006-06-13 | use of a compound |
NO20076075A NO20076075L (en) | 2005-06-24 | 2007-11-27 | 4-Anilino-3-quinoline carbonitriles for the treatment of cancer |
IL187792A IL187792A0 (en) | 2005-06-24 | 2007-11-29 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69367105P | 2005-06-24 | 2005-06-24 | |
US60/693,671 | 2005-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007001839A2 true WO2007001839A2 (en) | 2007-01-04 |
WO2007001839A3 WO2007001839A3 (en) | 2007-04-26 |
Family
ID=37575124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/023063 WO2007001839A2 (en) | 2005-06-24 | 2006-06-13 | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer |
Country Status (20)
Country | Link |
---|---|
US (1) | US20070010527A1 (en) |
EP (1) | EP1893209A2 (en) |
JP (1) | JP2008546777A (en) |
KR (1) | KR20080027275A (en) |
CN (1) | CN101252931A (en) |
AR (1) | AR057403A1 (en) |
AU (1) | AU2006262591A1 (en) |
BR (1) | BRPI0611977A2 (en) |
CA (1) | CA2610209A1 (en) |
CR (1) | CR9539A (en) |
EC (1) | ECSP078015A (en) |
GT (1) | GT200600268A (en) |
IL (1) | IL187792A0 (en) |
MX (1) | MX2007016542A (en) |
NI (1) | NI200700323A (en) |
NO (1) | NO20076075L (en) |
PE (1) | PE20070323A1 (en) |
RU (1) | RU2007143434A (en) |
TW (1) | TW200730177A (en) |
WO (1) | WO2007001839A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445496B2 (en) | 2005-07-01 | 2013-05-21 | Wyeth Llc | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
WO2017134679A1 (en) * | 2016-02-03 | 2017-08-10 | Msn Laboratories Private Limited | Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
CN107433391B (en) * | 2017-07-03 | 2020-01-17 | 武汉逸飞激光设备有限公司 | Welding calibration method and system based on image recognition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046693A1 (en) * | 2003-11-06 | 2005-05-26 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6432979B1 (en) * | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2006
- 2006-06-13 BR BRPI0611977-8A patent/BRPI0611977A2/en not_active IP Right Cessation
- 2006-06-13 EP EP06773093A patent/EP1893209A2/en not_active Withdrawn
- 2006-06-13 AU AU2006262591A patent/AU2006262591A1/en not_active Abandoned
- 2006-06-13 WO PCT/US2006/023063 patent/WO2007001839A2/en active Application Filing
- 2006-06-13 KR KR1020077030196A patent/KR20080027275A/en not_active Application Discontinuation
- 2006-06-13 MX MX2007016542A patent/MX2007016542A/en not_active Application Discontinuation
- 2006-06-13 RU RU2007143434/14A patent/RU2007143434A/en not_active Application Discontinuation
- 2006-06-13 JP JP2008518219A patent/JP2008546777A/en active Pending
- 2006-06-13 CN CNA2006800223605A patent/CN101252931A/en active Pending
- 2006-06-13 CA CA002610209A patent/CA2610209A1/en not_active Abandoned
- 2006-06-22 PE PE2006000716A patent/PE20070323A1/en not_active Application Discontinuation
- 2006-06-22 TW TW095122482A patent/TW200730177A/en unknown
- 2006-06-22 GT GT200600268A patent/GT200600268A/en unknown
- 2006-06-22 US US11/473,540 patent/US20070010527A1/en not_active Abandoned
- 2006-06-23 AR ARP060102728A patent/AR057403A1/en not_active Application Discontinuation
-
2007
- 2007-11-22 CR CR9539A patent/CR9539A/en not_active Application Discontinuation
- 2007-11-27 NO NO20076075A patent/NO20076075L/en not_active Application Discontinuation
- 2007-11-29 IL IL187792A patent/IL187792A0/en unknown
- 2007-12-14 EC EC2007008015A patent/ECSP078015A/en unknown
- 2007-12-14 NI NI200700323A patent/NI200700323A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046693A1 (en) * | 2003-11-06 | 2005-05-26 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
Non-Patent Citations (3)
Title |
---|
BOSCHELLI, D.H.: "4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors- An Update" MEDICINAL CHEMISTRY REVIEWS ONLINE, vol. 1, no. 4, 2004, pages 457-463, XP009076846 * |
GOLAS J M ET AL: "SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases,Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 2, 2003, pages 375-381, XP002283612 ISSN: 0008-5472 * |
GOLAS, J.M. ET AL.: "SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models" CANCER RESEARCH, vol. 65, no. 12, 15 June 2005 (2005-06-15), pages 5358-5364, XP002413906 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445496B2 (en) | 2005-07-01 | 2013-05-21 | Wyeth Llc | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
WO2017134679A1 (en) * | 2016-02-03 | 2017-08-10 | Msn Laboratories Private Limited | Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20080027275A (en) | 2008-03-26 |
NO20076075L (en) | 2008-03-18 |
AR057403A1 (en) | 2007-12-05 |
CA2610209A1 (en) | 2007-01-04 |
TW200730177A (en) | 2007-08-16 |
GT200600268A (en) | 2007-06-18 |
US20070010527A1 (en) | 2007-01-11 |
CN101252931A (en) | 2008-08-27 |
ECSP078015A (en) | 2008-01-23 |
NI200700323A (en) | 2008-06-25 |
CR9539A (en) | 2008-02-20 |
BRPI0611977A2 (en) | 2010-10-13 |
JP2008546777A (en) | 2008-12-25 |
PE20070323A1 (en) | 2007-05-04 |
IL187792A0 (en) | 2008-11-03 |
EP1893209A2 (en) | 2008-03-05 |
AU2006262591A1 (en) | 2007-01-04 |
RU2007143434A (en) | 2009-07-27 |
MX2007016542A (en) | 2008-03-04 |
WO2007001839A3 (en) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230226039A1 (en) | Method for treating gefitinib resistant cancer | |
Burslem et al. | The advantages of targeted protein degradation over inhibition: an RTK case study | |
US7919625B2 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | |
US9273031B2 (en) | Combination therapy with MDM2 and EFGR inhibitors | |
JP2002538107A (en) | JAK-3 inhibitor for treating allergic disorders | |
US20140024030A1 (en) | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status | |
US20060235046A1 (en) | Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients | |
JP2015525063A (en) | Pre-selection of subjects for treatment with HSP90 inhibitors based on hypoxia | |
US20070010527A1 (en) | 4-Anilino-3-quinolinecarbonitriles for the treatment of cancer | |
CN106794180A (en) | Conjoint therapy | |
JP2003512607A (en) | Allosteric site of muscarinic receptor | |
EP2608792B1 (en) | Methods of administering an egfr inhibitor | |
Beyett et al. | Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase | |
Sanchala et al. | Therapeutic approaches for the treatment of epidermal growth factor receptor mutated lung cancer | |
WO2008060283A1 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) | |
WO2008064004A2 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) | |
US20230212124A1 (en) | Small-molecule inhibitors of the frs2-fgfr interaction | |
Galimberti et al. | CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma | |
US20080119463A1 (en) | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) | |
TW202400153A (en) | Therapeutic uses of a krasg12c inhibitor | |
WO2021205363A1 (en) | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680022360.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009539 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2610209 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187792 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006773093 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4727/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006262591 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 564220 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07132342 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/016542 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502886 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2008518219 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077030196 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006262591 Country of ref document: AU Date of ref document: 20060613 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007143434 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0611977 Country of ref document: BR Kind code of ref document: A2 |